Changing the Practice of Medicine
Popular
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Chan Y. Cheah, MBBS
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
CME/CE
- MinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
1.00 program creditScott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
- MinuteCE®
IBD Care Reimagined: Personalized, Proactive, and Target-Driven Management
2.00 credits 13 episodesDavid T. Rubin, MD
Michael Dolinger, MD, MBA
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Michael Dolinger, MD, MBA
Florence Odufalu, MD
Michael Dolinger, MD, MBA
David T. Rubin, MD
Clinical Practice
Alessandra Tedeschi, MD
Aditya Bardia, MD, MPH, FASCO
- Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
Michael Dolinger, MD, MBA
David T. Rubin, MD
Florence Odufalu, MD
David T. Rubin, MD
Programs
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
- Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
- CME/CE Broadcast Replay
Seeing the Invisible: Radiologic Precision to Enable Early Intervention in Bronchiectasis
1.00 creditRobert D. Suh, MD
Ashwin Basavaraj, MD
Mary Salvatore, MD, MBA
Michael Dolinger, MD, MBA
David T. Rubin, MD
Michael Dolinger, MD, MBA
David T. Rubin, MD
- MinuteCE®
Translating Advances into Practice: Lessons from Today’s IBD Landscape
2.00 program creditsUgo Iroku, MD, MHS
David T. Rubin, MD